Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.

By K. Wollert, G. Meyer, J. Lotz, Stefanie Ringes‐Lichtenberg, P. Lippolt, C. Breidenbach, S. Fichtner, T. Korte, B. Hornig, D. Messinger and 4 more. The Lancet, 2004

2,293 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/84834d4bfffc2b3a497a6829567719641ad6c076

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. (2005, background): “Consistently, initial clinical trials indicate that bone marrowderived or circulating blood-derived progenitor cells are therapeutically useful to improve heart function [13,42].”
From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells (2007, background): “The authors suggested that autologous bone marrow cells can be used to enhance left ventricular functional recovery in patients that had acute heart infarction (Wollert et al., 2004).”
Challenges in tissue engineering (2006, background): “…osteoarthritic knee cartilage (Wakitani et al. 2002), osteochondritis dissecans (Ochi et al. 2002; Peterson et al. 2003), myocardial infarction (Wollert et al. 2004), vascular conduits for extracardiac Fontan operation (Shin’oka et al. 2001; Naito et al. 2003; Matsumura et al. 2003) and…”
Which white blood cell subtypes predict increased cardiovascular risk? (2005, background): “Recent human trials using intracoronary transfer of autologous bone marrow, rich in hematopoietic and mesenchymal precursor cells, have suggested a benefit after MI (30, 31 ) and have postulated to represent augmentation of intrinsic reparative processes.”
Stem cell plasticity: time for a reappraisal? (2005, positive): “evaluated six months after a percutaneous coronary intervention.(95) However, though neoangiogenesis from BM-derived SC seems to be well established, the”
Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. (2005, background): “Despite the recent negative reports about transdifferentiation (3, 16, 36), clinical trials with bone marrow-derived cell populations have been published and in part proven effective in the treatment of myocardial infarction (31, 33, 39).”
Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. (2008, methodology): “Experimental groups were divided into four groups of 10 rats each: (1) MI with transplant of normoxic MSCs (N-MSCs), (2) MI with transplant of hypoxia-pretreated MSCs (H-MSCs), (3) MI with injection of control medium, and ( 4 ) sham-operated control group.”
Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis (2010, background): “Clinical trials have revealed the feasibility and safety of the clinical use of MSCs (for review, see Giordano et al(27)) and have provided some evidence of efficacy in various medical conditions.(28-34) On the basis of the preclinical experience and the cumulative data from clinical studies,(28-39)”